(Reuters) - Johnson & Johnson (NYSE: JNJ) said on Monday it had filed a lawsuit against Samsung (KS: 005930) Bioepis for breaching its contract agreement with the drugmaker over the launch of a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider.

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. Selarsdi, like Stelara, is approved for the ...